EDGAR·FLOW

Tyra Biosciences, Inc. — Form 8-K

Filed November 10, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Tyra Biosciences completed a $400M underwritten public offering in September 2026 (led by RA Capital Management) and reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC: 79% overall response rate and 64% complete response rate at 60 mg QD (n=14), with 100% ORR and 75% CR among single-lesion patients (n=8); no Grade 3 treatment-related adverse events at this dose. Cash position is now $700.5M as of September 30, 2026, funding operations through 2030. Q3 2026 net loss was $51.1M vs. $29.9M in Q3 2025; R&D expenses increased 69% YoY to $43.1M.
Why this rating

Financing of $400M is 135% of market cap; strong early clinical efficacy data with favorable safety supports Phase 3 pathway. Material near-term catalyst, but company remains pre-approval with execution risk.

Tradability signal
NO TRADE

No trade: positive news with only -2.4% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.40% over 4 hrs, n=417). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$22.18
+10 min · unknown
$21.81 ▼ 1.65%
+30 min · unknown
$22.49 ▲ 1.42%
+1 hr · unknown
$21.54 ▼ 2.86%
+4 hrs · unknown
$20.88 ▼ 5.84%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ TYRA · stock on Yahoo Finance ↗

See more from November 10, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.